Introduction

If you have been told you have cartilage damage in your knee, hip, shoulder or ankle, the question that matters most is a practical one: is there a way to repair or preserve the joint before you need a replacement? Regenerative orthopaedics has developed credible answers to that question, and the range of options has widened considerably in recent years. The challenge is understanding what each option actually involves — particularly since two treatments that appear in the same conversation, ChondroFiller and Liquid Cartilage, are genuinely different things.

This article explains the Regeneration-First philosophy that shapes care at the London Cartilage Clinic, describes the diagnostic process, and sets out clearly what ChondroFiller and Liquid Cartilage each are and how they differ.

The Thinking Behind Regeneration-First Cartilage Care

The heart of the Regeneration-First philosophy is straightforward: before turning to joint replacement, explore whether the body can be supported to repair its own cartilage. Cartilage — the smooth tissue that cushions joint surfaces and allows pain-free movement — has a limited natural ability to heal once damaged, because it has no direct blood supply. Regenerative approaches aim to fill that gap by providing the structural or biological environment the tissue needs to recover.

Scientific evidence increasingly supports the principle. Published studies in tissue engineering and regenerative orthopaedics suggest that biologically based interventions, including scaffold-based repair and cell-augmented techniques, can produce clinically meaningful improvement in joint function for carefully selected patients. The emphasis on individualisation matters: what works well for a contained focal defect in a younger, active patient may not be appropriate for advanced, diffuse osteoarthritis.

Each treatment plan is supported by published evidence, tailored to the individual, and delivered by experienced clinicians. Outcomes vary and no biological treatment guarantees a cure or the reversal of arthritis, but for the right patient at the right stage, evidence suggests these approaches can preserve the joint and reduce symptoms for a meaningful period.

Thorough and Personalised Diagnosis

A good outcome from any regenerative procedure depends heavily on accurate assessment beforehand. The diagnostic workup at the London Cartilage Clinic combines clinical examination with advanced technology.

Biomechanical evaluation examines how your joints function during movement, identifying imbalances or load-distribution problems that can accelerate cartilage wear. Advanced motion-capture systems give the clinical team a detailed picture of joint mechanics beyond what a static examination reveals.

AI-assisted imaging provides high-resolution scans that allow the team to assess cartilage condition, defect size, location and depth with precision. These findings directly inform which treatment pathway — injection or surgery — is most appropriate for each patient.

The assessment also considers the patient's activity level, age, alignment, joint stability and overall health, since all of these influence both candidacy and the likely trajectory of repair.

Two Distinct Treatment Pathways: ChondroFiller Injection and Liquid Cartilage Surgery

Understanding the difference between these two pathways is essential, because they are often mentioned together and are sometimes confused. They are not synonyms, nor is one simply the branded name for the other. They serve different clinical situations and involve different levels of intervention.

ChondroFiller Injection (Non-Surgical)

ChondroFiller is a Class III CE-marked type I collagen hydrogel scaffold, manufactured by Meidrix Biomedicals in Germany and imported into the UK under prescription. It is an acellular device — it contains no cells of its own — that self-gels within approximately three to five minutes of application, forming a porous three-dimensional matrix inside the cartilage defect. The scaffold acts as a chemotactic signal, recruiting the patient's own progenitor cells to migrate in, differentiate into chondrocyte-like cells, and progressively replace the scaffold with new cartilage tissue over a period of one to two years.

The ChondroFiller injection is the non-surgical delivery pathway. It is performed as an ultrasound-guided outpatient procedure, with no theatre, no incision, and no general anaesthetic. The collagen gel is injected directly into the defect under image guidance. This approach suits accessible lesions and smaller joints where the defect can be reliably reached without arthroscopy. CE marking, the device safety record and the published clinical outcome data (IKDC improvement of approximately 30 points over 12 to 36 months in the knee; modified Harris Hip Score improvement of over 30 points in the hip) belong to ChondroFiller as the approved device.

Liquid Cartilage (Keyhole Surgery)

Liquid Cartilage is not a product. It is Professor Paul Lee's surgical technique protocol — the Lee Liquid Cartilage Protocol (LLC Protocol) — and it is a genuine keyhole (arthroscopic) surgical procedure performed under anaesthetic in a theatre setting. It uses ChondroFiller as its core scaffold, but it combines that scaffold with a carefully structured set of biological adjuncts and a peri-operative optimisation programme.

The surgical steps are designed around what Professor Lee describes as the physics, chemistry and biology of cartilage repair. The joint is prepared arthroscopically: unstable cartilage is debrided, a stable vertical rim is created, and the chamber is dried, typically by switching from saline irrigation to carbon dioxide insufflation. The defect surface is primed with autologous platelet-rich fibrin before the ChondroFiller scaffold is injected under dry conditions and allowed to gel. Once stable, platelet-rich plasma combined with tranexamic acid is introduced into the joint to reinforce anchorage and limit haemarthrosis. Where indicated — particularly for larger or more challenging defects — the patient's own mesenchymal stem cells, derived from bone-marrow aspirate concentrate (BMAC) or micro-fragmented adipose tissue, are added to the primed defect before scaffold placement.

The protocol extends beyond the operating theatre. Peri-operative preparation includes nutritional optimisation and avoidance of medications that blunt platelet function. Structured rehabilitation follows, typically involving protected weight-bearing for the first two weeks, progressive physiotherapy and neuromuscular activation from day zero, and a return-to-sport pathway spanning several months. The Liquid Cartilage protocol is used for larger or load-bearing defects in joints such as the knee, hip, shoulder and ankle — situations where the injection-only approach would be insufficient.

Choosing Between the Two Pathways

The decision between the ChondroFiller injection and the Liquid Cartilage surgical protocol depends on the size and location of the defect, the joint involved, and the patient's overall clinical picture. Smaller, accessible lesions in patients who are not candidates for general anaesthetic may be well served by the injection approach. Larger defects, those in load-bearing positions, or those requiring debridement and biological augmentation are better addressed through the surgical protocol.

Both pathways share the same underlying material — the ChondroFiller collagen scaffold — and the same biological principle of recruiting the body's own cells to regenerate cartilage. The difference lies in the surgical precision, the biological layering and the structured rehabilitation that the Liquid Cartilage protocol adds.

Supporting Patients Throughout Treatment

Whether the pathway chosen is the injection or the surgical protocol, patients are supported with clear communication and education from the first consultation. The team at the London Cartilage Clinic includes physiotherapists, rehabilitation specialists and referring clinicians, and care is coordinated across these disciplines to ensure a coherent recovery plan. Patients benefit from structured guidance not only during the treatment itself, but through the rehabilitation phase as new cartilage tissue matures.

The clinic works closely with referring GPs and sports medicine clinicians to ensure continuity of care, and treatment plans are reviewed as recovery progresses.

Conclusion

Professor Paul Lee's Regeneration-First approach offers a structured, evidence-informed alternative to early joint replacement for patients with focal cartilage damage. The key to navigating it is understanding the two distinct pathways it encompasses: the ChondroFiller injection, a non-surgical outpatient procedure for accessible or smaller lesions, and the Liquid Cartilage surgical protocol, a keyhole technique that combines the same collagen scaffold with biological augmentation and a full peri-operative system for more complex cases.

For patients seeking a specialist assessment of their cartilage condition and guidance on which approach, if any, may be appropriate for them, the London Cartilage Clinic on Harley Street offers a comprehensive evaluation. Speaking with a specialist remains the right starting point for any individual medical decision.

References

Tuan, R. S., Chen, A. F., & Klatt, B. A. (2013). Cartilage Regeneration. Journal of the American Academy of Orthopaedic Surgeons, 21(5), 303–311.